Jonathan G. Drachman
Net Worth

Last updated:

What is Jonathan G. Drachman net worth?

The estimated net worth of Dr. Jonathan G. Drachman is at least $3,830,580 as of 25 Aug 2021. He has received compensation worth at least $3,830,580 in Neoleukin Therapeutics, Inc..

What is the salary of Jonathan G. Drachman?

Dr. Jonathan G. Drachman salary is $638,430 per year as Chief Executive Officer, Pres & Director in Neoleukin Therapeutics, Inc..

How old is Jonathan G. Drachman?

Dr. Jonathan G. Drachman is 63 years old, born in 1962.

What stocks does Jonathan G. Drachman currently own?

As insider, Dr. Jonathan G. Drachman owns shares in one company:

Company Title Shares Price per share Total value
Neoleukin Therapeutics, Inc. (NLTX) Chief Executive Officer, Pres & Director 25,000 $0 $0

What does Neoleukin Therapeutics, Inc. do?

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Jonathan G. Drachman insider trading

Neoleukin Therapeutics, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 25,000 $6.45 $161,225
Purchase
Common Stock 100,000 $6.11 $611,100
Purchase
Common Stock 10,000 $9.61 $96,080
Purchase
Common Stock 40,000 $9.48 $379,280
Purchase
Common Stock 119,047 $8.4 $999,995
Purchase
Common Stock 136,436 $3.3 $449,966
Purchase
Common Stock 36,742 $3.08 $113,276
Purchase
Common Stock 76,822 $2.85 $218,559

Neoleukin Therapeutics key executives

Neoleukin Therapeutics, Inc. executives and other stock owners filed with the SEC: